Drug & intervention

methadone

RxCUI 6813

Clinical trials14
Recruiting0
Related conditions20
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…
Background context

Methadone

Methadone, sold under the brand names Dolophine and Methadose, among others, is a potent synthetic opioid used medically to treat chronic pain and opioid use disorder. Prescribed for daily use, the medicine relieves cravings and opioid withdrawal symptoms. Withdrawal management using methadone can be accomplished in less than a month, or it may be done gradually over a longer period of time, or simply maintained for the rest of the patient's life. While a single dose has a rapid effect, maximum effect can take up to five days of use. After long-term use, in people with normal liver function, effects last 8 to 36 hours. Methadone is usually taken by mouth and rarely by injection into a muscle or vein. Side effects are similar to those of other opioids. These frequently include dizziness, sleepiness, nausea, vomiting, and sweating. Serious risks include opioid abuse and respiratory depression. Abnormal heart rhythms may also occur due to a prolonged QT interval. The number of deaths in the United States involving methadone poisoning declined from 4,418 in 2011 to 3,300 in 2015. Risks are greater with higher doses. Methadone is made by chemical synthesis and acts on opioid receptors. Methadone was developed in Germany in the late 1930s by Gustav Ehrhart and Max Bockmühl. It was approved for use as an analgesic in the United States in 1947, and has been used in the treatment of addiction since the 1960s. It is on the World Health Organization's List of Essential Medicines.

Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

14 shown
Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1NCT04480554 · 2023-01-30
TERMINATED
Effect of Heroin Use on Immune Activation and Cardiovascular Risk in HIVNCT03976258 · 2017-07-14
COMPLETED
A Study to Assess the Drug-drug Interaction of BMS 663068 With Methadone and Also With Buprenorphine/NaloxoneNCT02666001 · 2016-01-12
COMPLETED
Effects of Doravirine (MK-1439) on Methadone Pharmacokinetics in Methadone-Maintained Participants (MK-1439-045)NCT02715700 · 2015-09-28
COMPLETED
Neurocognitive Effects of Opiate Agonist TreatmentNCT01733693 · 2013-01-01
COMPLETED
Diversion to Treatment for Injection Drug Users Arrested for Possession of HeroinNCT01723527 · 2012-12-01
COMPLETED
Reducing Drug Use and HIV Risk in Drug-dependent Adults Arrested for ProstitutionNCT01560221 · 2012-10-01
COMPLETED
Methadone-Dolutegravir (DTG - GSK1349572) Drug Interaction Study.NCT01467518 · 2011-12-01
COMPLETED
HIV Risk Reduction in Subutex Injectors in TbilisiNCT01131273 · 2010-06-01
COMPLETED
Intervention of HIV, Drug Use and the Criminal Justice System in MalaysiaNCT02396979 · 2010-01-01
COMPLETED
Combination Pain Therapy in HIV NeuropathyNCT00863057 · 2009-05-01
TERMINATED
Combination of an Investigational Cannabinoid and Methadone for HIV-associated NeuropathyNCT00723918 · 2009-04-01
WITHDRAWN
Methadone Maintenance & HIV Risk in UkraineNCT00351026 · 2008-06-01
COMPLETED
Treatment of Heroin and Cocaine With Methadone Maintenance and Contingency ManagementNCT00292110 · 2004-02-01
COMPLETED

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.